EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

EssexBio Bolsters Commitment to Ophthalmology Innovation at APAO 2026 in Hong Kong

2026.02.10

EssexBio to Participate in APAO 2026 and Showcase Key Ophthalmology Assets

2026.01.22

EssexBio Forms Strategic Cooperation with Kenvue for Motrin®, Tylenol® and Rhinocort®

2025.12.17

Essex Bio-Technology establishes strategic collaboration with Biosparc Signs MOU with SIPIPO and Biosparc on International Innovation Accelerator

2025.11.21

Date

Title

2023-04-14

Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore

2023-04-11

Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC® Absorbable Dressing in Mainland China

2023-03-08

Essex Bio-Technology (1061.HK) 2022 Annual Results at a glance

2023-03-08

Essex Bio-Technology Announces 2022 Annual Financial Results, Resilience & Relevance, Growth Ready

2023-02-23

2023-02-22

Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration

2023-02-10

First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases

2022-10-13

Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT